Vaz, Sofia C. http://orcid.org/0000-0003-4229-9349
Woll, John Patrick Pilkington http://orcid.org/0000-0002-0891-331X
Cardoso, Fatima http://orcid.org/0000-0002-6692-2249
Groheux, David http://orcid.org/0000-0002-9541-9175
Cook, Gary J. R. http://orcid.org/0000-0002-8732-8134
Ulaner, Gary A. http://orcid.org/0000-0002-7953-0113
Jacene, Heather http://orcid.org/0000-0001-7167-078X
Rubio, Isabel T. http://orcid.org/0000-0003-0035-0679
Schoones, Jan W. http://orcid.org/0000-0003-1120-4781
Peeters, Marie-Jeanne Vrancken http://orcid.org/0000-0003-4472-4257
Poortmans, Philip http://orcid.org/0000-0001-7400-2293
Mann, Ritse M. http://orcid.org/0000-0001-8111-1930
Graff, Stephanie L. http://orcid.org/0000-0003-1928-1722
Dibble, Elizabeth H. http://orcid.org/0000-0002-3906-6272
de Geus-Oei, Lioe-Fee http://orcid.org/0000-0003-1817-2743
Article History
Received: 11 January 2024
Accepted: 20 March 2024
First Online: 14 May 2024
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Gary Cook: research grant from Breast Cancer Now and he was a previous member of their scientific advisory board.Gary Ulaner: Consultant/Advisory Board/Research Funding – GE Healthcare, Lantheus, ImaginAb, Point BiopharmaHeather Jacene: Blue Earth Diagnostics, honoraria and research support; Consulting, advanced accelerator applications, spectrum dynamics, royalties: Cambridge University Press; all are not related to the work presented in this manuscript.Philip Poortmans: medical advisor of Sordina IORT Technologies S.p.A., not related to the work presented in this manuscript.Ritse Mann: research grants from/with Beckton and Dickinson, Siemens, Bayer Healthcare, Screenpoint medical, Koning, and PA Imaging, and is a medical advisor to Screenpoint, Bayer, Guerbet, and BD. All are unrelated to the work in this manuscript.Fatima Cardoso: Personal financial interest in form of consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime.Institutional financial support for clinical trials from: Amgen, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo, Eisai, Fresenius GmbH, Genentech, Gilead, GlaxoSmithKline, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Novartis, Macrogenics, Medigene, MedImmune, Merck, Millenium, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Sonus, Tesaro, Tigris, Wilex, Wyeth.All the other authors declare no conflict of interest.
: This guideline has been reviewed and endorsed by the following societies: American College of Radiology (ACR), European Society of Surgical Oncology (ESSO), European Society for Radiotherapy and Oncology (ESTRO), European Society of Breast Imaging/ European Society of Radiology (EUSOBI/ESR), and European Society of Breast Cancer Specialists (EUSOMA).
: This guideline summarizes the views of the EANM Oncology and Theranostics Committee and SNMMI. It reflects recommendations for which the EANM and SNMMI cannot be held responsible. The recommendations should be taken into the context of good practice of the different disciplines (mainly Nuclear Medicine, Breast Radiology, Radiation Oncology, Medical Oncology, and Breast Surgery) and do not substitute for national and international legal or regulatory provisions.